1
|
Senisterra G, Zhu HY, Luo X, Zhang H, Xun G, Lu C, Xiao W, Hajian T, Loppnau P, Chau I, Li F, Allali-Hassani A, Atadja P, Oyang C, Li E, Brown PJ, Arrowsmith CH, Zhao K, Yu Z, Vedadi M. Discovery of Small-Molecule Antagonists of the H3K9me3 Binding to UHRF1 Tandem Tudor Domain. SLAS Discov 2018; 23:930-940. [PMID: 29562800 DOI: 10.1177/2472555218766278] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Ubiquitin-like with PHD and RING finger domains 1 (UHRF1) is a multidomain protein that plays a critical role in maintaining DNA methylation patterns through concurrent recognition of hemimethylated DNA and histone marks by various domains, and recruitment of DNA methyltransferase 1 (DNMT1). UHRF1 is overexpressed in various cancers, including breast cancer. The tandem tudor domain (TTD) of UHRF1 specifically and tightly binds to histone H3 di- or trimethylated at lysine 9 (H3K9me2 or H3K9me3, respectively), and this binding is essential for UHRF1 function. We developed an H3K9me3 peptide displacement assay, which was used to screen a library of 44,000 compounds for small molecules that disrupt the UHRF1-H3K9me3 interaction. This screen resulted in the identification of NV01, which bound to UHRF1-TTD with a Kd value of 5 μM. The structure of UHRF1-TTD in complex with NV01 confirmed binding to the H3K9me3-binding pocket. Limited structure-based optimization of NV01 led to the discovery of NV03 (Kd of 2.4 μM). These well-characterized small-molecule antagonists of the UHRF1-H3K9me2/3 interaction could be valuable starting chemical matter for developing more potent and cell-active probes toward further characterizing UHRF1 function, with possible applications as anticancer therapeutics.
Collapse
Affiliation(s)
| | - Hugh Y Zhu
- 2 Novartis Institutes for BioMedical Research (China), Pudong, Shanghai, China
| | - Xiao Luo
- 2 Novartis Institutes for BioMedical Research (China), Pudong, Shanghai, China
| | - Hailong Zhang
- 2 Novartis Institutes for BioMedical Research (China), Pudong, Shanghai, China
| | - Guoliang Xun
- 2 Novartis Institutes for BioMedical Research (China), Pudong, Shanghai, China
| | - Chunliang Lu
- 2 Novartis Institutes for BioMedical Research (China), Pudong, Shanghai, China
| | - Wen Xiao
- 2 Novartis Institutes for BioMedical Research (China), Pudong, Shanghai, China
| | - Taraneh Hajian
- 1 Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada
| | - Peter Loppnau
- 1 Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada
| | - Irene Chau
- 1 Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada
| | - Fengling Li
- 1 Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada
| | | | - Peter Atadja
- 2 Novartis Institutes for BioMedical Research (China), Pudong, Shanghai, China
| | - Counde Oyang
- 2 Novartis Institutes for BioMedical Research (China), Pudong, Shanghai, China
| | - En Li
- 2 Novartis Institutes for BioMedical Research (China), Pudong, Shanghai, China
| | - Peter J Brown
- 1 Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada
| | - Cheryl H Arrowsmith
- 1 Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada.,3 Princess Margaret Cancer Centre and Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
| | - Kehao Zhao
- 2 Novartis Institutes for BioMedical Research (China), Pudong, Shanghai, China.,4 School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, China
| | - Zhengtian Yu
- 2 Novartis Institutes for BioMedical Research (China), Pudong, Shanghai, China
| | - Masoud Vedadi
- 1 Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada.,5 Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
2
|
Bronner C, Krifa M, Mousli M. Increasing role of UHRF1 in the reading and inheritance of the epigenetic code as well as in tumorogenesis. Biochem Pharmacol 2013; 86:1643-9. [PMID: 24134914 DOI: 10.1016/j.bcp.2013.10.002] [Citation(s) in RCA: 85] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2013] [Revised: 10/01/2013] [Accepted: 10/01/2013] [Indexed: 12/30/2022]
Abstract
Epigenetic mechanisms such as DNA methylation and histone posttranslational modifications, allow cells to maintain the phenotype throughout successive mitosis. UHRF1 plays a major role in the inheritance of some epigenetic marks from mother cells to daughter cells due to its particular structural domains. The originality of UHRF1 lies in the fact that it can read epigenetic marks and recruit the enzymes that catalyze the same epigenetic mark. The SRA domain senses the presence of a methylated cytosine on one DNA strand allowing the recruitment of DNMT1, which methylates the cytosine on the newly synthesized DNA. The recently identified tudor domain of UHRF1 senses the presence of methylated histone H3 conducting UHRF1 to recruit histone methyltransferases. Recent studies deciphering the relationships between some of the structural domains of UHRF1 provides new insights on the reading of the epigenetic code over a larger portion of histone tail than usually expected. Furthermore, latest developments highlights that UHRF1 is one of the proteins which is able to directly connect DNA methylation to histone epigenetic marks. This paper reviews the principles how UHRF1 acts as an epigenetic reader and discusses the properties of UHRF1 to be a biomarker as well as a therapeutic target.
Collapse
Affiliation(s)
- Christian Bronner
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, the Centre National de la Recherche Scientifique UMR7104, the Institut National de la Santé et de la Recherche Médicale U964, Université de Strasbourg, Parc d'innovation, 1 rue Laurent Fries, 67404 Illkirch Cedex, France.
| | | | | |
Collapse
|